Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18986271 | 0.84 | TYR (0.45) | TYRCA12CA1CA2CA7 | |
| SCHEMBL13323826 | 0.84 | ESR2 (0.42) | TYRMEN1KMT2AFFAR1 | |
| SCHEMBL27977148 | 0.83 | TYR (0.45) | TYRCA12CA1CA2CA7 | |
| SCHEMBL18986203 | 0.83 | TYR (0.42) | TYRCA12CA1CA2CA7 | |
| SCHEMBL30112151 | 0.83 | TYR (0.47) | TYRCA12CA1CA2CA7 | |
| SCHEMBL21903498 | 0.83 | TYR (0.47) | TYRCA12CA1CA2CA7 | |
| SCHEMBL22823679 | 0.83 | FFAR1 (0.42) | TYRFFAR1 | |
| SCHEMBL16790333 | 0.83 | FFAR1 (0.37) | TYRCA12CA1CA2CA7 | |
| SCHEMBL18986193 | 0.82 | TYR (0.41) | TYRCA12CA1CA2CA7 | |
| SCHEMBL3240781 | 0.81 | CA12 (0.45) | TYRCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718594-B1 | Process for making coumarin derived compounds | UNILEVER PLC (GB) | 2015-06-10 | — | — | EP | disclosed |
| EP-1718594-B1 | Process for making coumarin derived compounds | UNILEVER PLC (GB) | 2015-06-10 | — | — | EP | disclosed |
| US-7723537-B2 | Skin lightening agents, compositions and methods | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723537-B2 | Skin lightening agents, compositions and methods | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723537-B2 | Skin lightening agents, compositions and methods | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080039636-A1 | Skin Lightening Agents, Compositions and Methods | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039636-A1 | Skin Lightening Agents, Compositions and Methods | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039636-A1 | Skin Lightening Agents, Compositions and Methods | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-7300646-B2 | Skin lightening agents, compositions and methods | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300646-B2 | Skin lightening agents, compositions and methods | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300646-B2 | Skin lightening agents, compositions and methods | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20050191250-A1 | Skin lightening agents, compositions and methods | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039636-A1 | Skin Lightening Agents, Compositions and Methods | HRH3, HRH4, HRH1 | TYR 17/4885CA12 1729/4885CA1 3195/4885 |
| US-20050191250-A1 | Skin lightening agents, compositions and methods | HRH3, HRH4, HRH1 | TYR 17/4885CA12 1729/4885CA1 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.